Get the Stockscreener App
14.12
8.67%
-1.34
After Hours:
14.12
Gh Research Plc stock is traded at $14.12, with a volume of 859.06K.
It is down -8.67% in the last 24 hours and down -5.17% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$15.46
Open:
$16.02
24h Volume:
859.06K
Relative Volume:
2.12
Market Cap:
$875.86M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-17.87
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
+12.96%
1M Performance:
-5.17%
6M Performance:
-5.33%
1Y Performance:
+56.89%
1-Day Range:
$13.50
$16.19
1-Week Range:
$12.39
$19.00
52-Week Range:
$7.98
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
14.12 | 958.97M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
GH Research (NASDAQ:GHRS) Stock Price Down 9.2%Should You Sell? - MarketBeat
GH Research stock rises as FDA lifts clinical hold on GH001 - Investing.com Australia
GH Research stock jumps as Canaccord raises price target on FDA hold lift - Investing.com
GH Research stock price target raised to $29 from $19 at Needham - Investing.com
GHRS Stock Sees Significant Price Target Increase by Needham | G - GuruFocus
GH Research (GHRS) Is Up 24.2% After FDA Lifts Hold On GH001 U.S. Trial Enrollment - simplywall.st
Hold lifted, as GH Research preps for pivotal GH-001 depression trial - BioWorld MedTech
GH Research stock rating reiterated as Buy by TD Cowen - Investing.com Nigeria
GH Research says FDA lifts clinical hold on GH001 - TipRanks
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - Benzinga
GH Research (NASDAQ:GHRS) Shares Gap UpTime to Buy? - MarketBeat
GH Research stock rises as Stifel reiterates Buy rating after clinical hold lifted By Investing.com - Investing.com South Africa
GH Research stock rises as FDA lifts clinical hold on inhaled 5-MeO-DMT - Investing.com UK
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Why is GHRS stock rising today? - MSN
US Stocks Higher; Dow Jumps 250 Points - Benzinga
GH Research stock rises as Stifel reiterates Buy rating after clinical hold lifted - Investing.com Nigeria
Why Is GH Research Stock Soaring Monday?GH Research (NASDAQ:GHRS) - Benzinga
Why Is GHRS Stock Rising Today? - Stocktwits
Why GH Research Is Rising In Pre-market? - Nasdaq
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Gh Research shares jump 44% premarket after US FDA lifts clinical hold on depression drug trials - marketscreener.com
GHRS: Needham Reiterates Buy Rating and $19 Price Target | GHRS Stock News - GuruFocus
GH Research surges as FDA lifts clinical hold on depression therapy - Seeking Alpha
GH Research (NASDAQ:GHRS) Receives Buy Rating from Needham & Company LLC - MarketBeat
GH Research Says FDA Lifted Clinical Hold on Investigational New Drug Application for GH001; Shares Rise Pre-Bell - marketscreener.com
GH Research Wins FDA Clearance to Advance GH001 for Treatment-Resistant Depression - TipRanks
GH Research stock soars after FDA lifts clinical hold on GH001 - Investing.com Australia
GH Research : Corporate Presentation - marketscreener.com
NextEra Energy, GH Research And 3 Stocks To Watch Heading Into Monday - Benzinga
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 - The Manila Times
Stock Market Today: S&P 500, Nasdaq Futures Rise, WTI Fluctuates Following US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus - Benzinga
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
What analysts say about GH Research PLC 1KA stockEnergy Sector Updates & Free Explosive Return Secrets - earlytimes.in
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision (NASDAQ:GHRS) - Seeking Alpha
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment - Stocktwits
GH Research stock rises on upcoming trial update (GHRS:NASDAQ) - Seeking Alpha
GH Research to provide update on FDA application for depression drug - Investing.com Nigeria
GH Research Shares Up, Plans to Provide Update on New Drug Application - marketscreener.com
GH Research Sets January 5 Update on IND Status and Phase 3 Plans for Lead TRD Drug GH001 - TipRanks
GH Research stock soars after IND update announcement By Investing.com - Investing.com Australia
GH Research stock soars after IND update announcement - Investing.com
GH Research PLC to Provide Update on IND Application and Phase 3 Program for GH001 in Treatment-Resistant Depression - Quiver Quantitative
Depression drug developer sets Jan. 5 update on key FDA filing - Stock Titan
GH Research sets January 5 update on IND status and phase 3 plans for lead TRD drug GH001 - MSN
GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Understanding the Setup: (GHRS) and Scalable Risk - Stock Traders Daily
Growth Recap: What dividend safety score for GH Research PLC stockJuly 2025 Trade Ideas & Reliable Trade Execution Plans - moha.gov.vn
MACD Cross Could Confirm Trend in RCC Cements LimitedMoving Average Strategies & Double Or Triple Investment - bollywoodhelpline.com
GH Research (GHRS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Fibonacci Levels Suggest Recovery for Euro Asia Exports LimitedSwing Trading Watchlist & Fast Growing Investment Plans - Bollywood Helpline
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):